869796-50-9

Upstream product

• 869796-52-1 methyl (S)-(3-(N-phenyl-N-2-pyridyl)amino)-2-(di-tert-butoxycarbonylamino)-propionate 
• 673488-57-8 (3-(N-phenyl-N-pyridin-2-yl)-amino)-2-(di-tert-butoxycarbonyl)-amino-propionic acid methyl ester 
• 669713-38-6 2-(2-methylaminopyrimidin-4-yl)-1H-indole-5-carboxylic acid 
• 673488-58-9 (S)-2-{[2-(2-methylamino-pyrimidin-4-yl)-1H-indole-5-carbonyl]-amino}-3-(phenyl-pyridin-2-yl-amino)-propionic acid methyl ester 

Downstream Products

• 899418-66-7 2-{[2-(2-methylaminopyrimidin-4-yl)-1H-indole-5-carbonyl]amino}-3-(phenylpyridin-2-yl-amino)propionic acid monopotassium salt monohydrate 

Relevant academic research and scientific papers

Substantially Pure 2-{[2-(2-Methylamino-Pyrimidin-4-YL)-1H-Indole-5-Carbonyl]-Amino}-3-Phenylpyridin-2-YL-Amino)-Propionic Acid as an IkB Kinase Inhibitor

The present invention is directed to the substantially pure compound of formula (A), or pharmaceutically acceptable salt, or solvate of said compound; to a pharmaceutical composition comprising a pharmaceutically effective amount of the compound of formul

SUBSTANTIALLY PURE 2-{[2-(2-METHYLAMINO-PYRIMIDIN-4-YL)-1H-INDOLE-5-CARBONYL]-AMINO}-3-(PHENYLPYRIDIN-2-YL-AMINO)-PROPIONIC ACID AS AN IKB KINASE INHIBITOR

The present invention is directed to the substantially pure compound of formula (A), or pharmaceutically acceptable salt, or solvate of said compound; to a pharmaceutical composition comprising a pharmaceutically effective amount of the compound of formul